Short answer
Vera Therapeutics, Inc. (VERA) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$109M
- −43.0% YoY · +9.6% QoQ
- EPS (diluted)
- −$1.53
- −27.5% YoY · +9.5% QoQ
Source: XBRL data from the Vera Therapeutics, Inc. (VERA) Q2 2026 10-Q on SEC EDGAR. USD.
Vera Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added commercialization risk triggered by TRUTAKNA’s July 7, 2026 FDA accelerated approval and first expected product revenue in Q3 2026
- Most materially updated operating risk: transition from clinical development to commercial operations, with no prior successful product commercialization experience
- Regulatory risk: accelerated approval for IgAN may require additional FDA post-approval evidence, potentially limiting continued marketing
- Near-term market risk: TRUTAKNA adoption depends on physician and patient acceptance, reimbursement, pricing, and competing therapies
- Financial risk: $499.2 million in cash, equivalents, and marketable securities versus $75.0 million outstanding debt as of June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vera Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.